At PDA/FDA Joint Regulatory Conference 2026, PCI Pharma's Bassler details how a QMS overhaul turned an FDA 483 into stronger quality culture.
|Articles|November 2, 2003
- Pharmaceutical Technology-11-02-2003
- Volume 27
- Issue 11
FDA Seeks Risk-Based Inspection Program
Author(s)Jill Wechsler
FDA's new policies intend to make GMP inspections more efficient and apply to stricter rules to high-risk products and processes.
Advertisement
Articles in this issue
almost 23 years ago
FDA Will Drive Changes for Contract Businessalmost 23 years ago
In the Spotlight--Decemberalmost 23 years ago
Novemember 2003almost 23 years ago
Routine Sample Size for a Retest Procedurealmost 23 years ago
November 2003almost 23 years ago
Clearing Regulatory Hurdlesalmost 23 years ago
Improving Protein Capture for Transgenic Drug ProcessingAdvertisement
Related to this article
Advertisement
Advertisement